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Summary
Objectives: To describe a method to study joint pain in experimental osteoarthritis (OA) and to study nitric oxide (NO) participation in exper-
imental OA.
Design: Rats were subjected to anterior cruciate ligament transection (ACLT) (OA group) of the right knee and evaluated during 28 days. A sham
group was false operated and a naive group received no manipulation. Joint pain was measured by recording the time the right hind paw fails to
touch the surface while walking. Cell inﬂux (CI) and nitrite levels were measured in joint exudates. Expression of inducible NO synthase (iNOS)
in synovia was detected by immunostaining. For the speciﬁc purpose of pharmacological manipulation, groups received either indomethacin
(2 mg/kg/day s.c. (subcutaneous)), meloxicam (6 mg/kg/day s.c.), morphine (200 mg intra-articularly), the non-selective NOS inhibitor L-N G-
nitroarginine methyl ester (L-NAME; 30 mg/kg/bid i.p. (intra-peritoneal)) or the selective iNOS inhibitor 1400W (0.5 mg/kg/day s.c.), given
30 min prior (prophylactic) or 4 days after (therapeutic) ACLT, until sacriﬁce, at 7 days. The respective non-treated groups received the vehicles.
Results: The OA group developed joint pain, as compared to sham and control groups (P< 0.05). Signiﬁcantly increased nitrite levels and
iNOS immunostaining were seen in the OA group. Both indomethacin and meloxicam inhibited joint pain (P< 0.05). Morphine inhibited joint
pain, whereas this effect was blocked by co-administration of the m-opioid receptor naloxone. CI was similar among all groups. Prophylactic
but not therapeutic L-NAME or 1400W reduced joint pain.
Conclusion: We describe a method to quantitate joint pain associated to weight bearing in the ACLT model. The joint pain is sensitive to
classical antinociceptive compounds. NO release is associated to joint pain though NOS inhibition does not inhibit ongoing pain.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a leading cause of disability in the
elderly. The treatment of this disease remains limited to
symptomatic relief and, ultimately, joint replacement. De-
spite the progress made in understanding the pathophysiol-
ogy of OA, effective disease-modifying drugs are still
lacking1. Although joint pain is the most frequent complaint
of OA patients as well as a leading cause of disability, the
pharmacological therapy of this symptom is still unsatis-
factory and relies on paracetamol, non-steroidal anti-inﬂam-
matory drugs, opioids, and corticosteroids1.
The mechanisms involved in pain in OA are multifactorial.
Cartilage degradation products may induce pain, either by
inducing local inﬂammation2 or by distension of the joint
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Received 21 August 2005; revision accepted 26 January 2006.7capsule3. The subchondral bone, due to its rich supply of
small-diameter nerve ﬁbers and non-adrenergic/non-cholin-
ergic innervation, has also been involved in the pain evoked
by OA patients4,5. Actually, subchondral ischemia and in-
creased venous pressure due to joint loading may induce
the liberation of non-adrenergic/non-cholinergic pain media-
tors, such as substance P and the calcitonin gene-related
peptide in the subjacent bone6.
Nitric oxide (NO) is a radical produced by a variety of
cells, including synoviocytes and chondrocytes7 and has
been shown to be involved in the pathophysiology of OA.
Raised levels of nitrite e used as a measurement of NO e
were reported both in serum and in the synovial ﬂuid of OA
patients8. Either NO per se or reactive species following NO
release may induce chondrocyte apoptosis9,10 and inhibit
aggrecan synthesis11, besides activating matrix metallopro-
teases12,13. Additionally, the participation of NO in nocicep-
tion, whether being analgesic or hyperalgesic, is still
controversial. While there are reports showing that NO
donors promoted pain relief in shoulder periarthritis,14
others have shown that intradermal administration of NO
donors induces hyperalgesia15. With regard to experimental69
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than NO synthase (NOS) inhibitors prevented the hyperal-
gesia in ongoing zymosan arthritis in rats16. However, to
our knowledge, there are no reports focusing on a possible
role for NO in mediating pain in OA.
The anterior cruciate ligament transection (ACLT) model
in rats has been used as an experimental OA model17. In
this model, swollen chondrocytes, ﬁbrillation of the articular
cartilage and chondrocyte loss were described as early as 7
days after ACLT. These changes progress at later stages
coupled to loss of proteoglycans from the articular cartilage
and denaturation of type II collagen ﬁbers. However, there
are no reports demonstrating the occurrence of joint pain
in this model. To our knowledge, attempts to quantify joint
pain in experimental OA were based on observation of
animals’ gait, using semiquantitative approaches18. Re-
cently, another tentative approach was reported, by an ad-
aptation of the paw-pressure test (RandalleSelitto’s test)
as well as through measuring tactile allodynia19 that may re-
ﬂect joint hyperalgesia, but may not properly reﬂect joint pain
secondary to OA changes. The articular incapacitation test,
deﬁned as the inability of a rat to walk normally after the in-
jection of an inﬂammatory stimulus into the knee joint, is an
easily reproducible, quantitative approach to measure joint
pain that is independent of the observer. It was originally de-
scribed using carrageenin as the inciting agent20 and we
have been using this method in the zymosan-induced arthri-
tis model16,21. In the present study, we adapted this method
to directly assess joint pain in the ACLT model in rats. Addi-
tionally, using this approach, we present evidence of NO
participation and that NOS inhibitors do not inhibit the
ongoing hypernociceptive response in this OA model.
Methods
ANIMALS
Male Wistar rats (180e200 g) from our own animal facil-
ities were used throughout the experiments. All efforts
were made to minimize animal suffering and the number
of animals used. The experimental protocol was approved
by our local ethics committee (protocol number 03/03) that
follows the guidelines of the Brazilian College of Animal
Experimentation.
ANTERIOR CRUCIATE LIGAMENT TRANSECTION
Animals were brieﬂy anesthetized under inhalation with
ether. After shaving of the right knee joint and local assepsia,
a parapatellar incision was made, followed by lateral dis-
placement of the patella, thereby providing access to the
joint space. The anterior cruciate ligament is then easily vis-
ible and was surgically excised. The increased anterior
displacement of the tibia in relation to the femur was used
to assure that the ligament was transected. The surgical
wound was then closed. A sham group was subjected to
the same surgical procedure, without the excision of the lig-
ament and a control (naive) group received no manipulation.
The animals were killed at various time intervals and the
results obtained in the group subjected to the ACLT (OA
group) were compared to both the sham and naive groups.
MEASUREMENT OF THE JOINT PAIN
We used the articular incapacitation method, as described
earlier, with slight modiﬁcations20. The animals were put to
walk on a steel rotary drum (30 cm wide 50 cm diameter),
which rotates at 3 rpm. Specially designed metal gaiterswere wrapped around both hind paws. After placement of
the gaiters, the animals were allowed to walk freely for habit-
uation. The right paw was then connected via a simple circuit
to a microcomputer data input/output port. The paw eleva-
tion time (PET), as recorded in the present study, is the
time in seconds that during a 10 min period the hind paw
is not in contact with the cylinder. This is assumed to give
a measure of joint pain. Results are reported either as the
mean of the maximal PET for a group of animals achieved
between 4 and 7 days or as the percent inhibition of the max-
imal PET obtained. This was assumed to represent the high-
est pain value in that particular period of evaluation.
COLLECTION OF SYNOVIAL EXUDATES AND SYNOVIAL
MEMBRANES
At 7 days after starting the experiment, the animals were
terminally anaesthetized (chloral hydrate 400 mg/kg i.p.
(intra-peritoneal)), killed by cervical dislocation, and ex-san-
guinated. The synovial cavity of the knee joints was then
washed with 0.4 ml phosphate-buffered saline (PBS) con-
taining 10 mM ethylenediaminetetraacetic acid. The syno-
vial exudates were collected by aspiration and total and
differential cell counts were performed using a Neubauer
chamber and stained smears, respectively. After centrifug-
ing (500 g/10 min), the supernatants were stored at 20(C
and used for determination of total nitrite/nitrate (NO2
/
NO3
) levels (see below). The synovial membranes were
surgically excised, parafﬁn embedded and routinely pro-
cessed for staining with hematoxylineeosin as well as for
the detection of the inducible NOS (iNOS) isoenzyme, using
immunohistochemistry (see below).
DETERMINATION OF NO PRODUCTION
The degree of NO production was determined as
a measure of total NO2
/NO3
 levels by the Griess reac-
tion. Total NO2
/NO3
 levels were determined, with the
NO3
 in the synovial exudates supernatants (0.08 ml) con-
verted to NO2
 by incubation of 0.01 ml nitrate reductase
from Aspergillus species (1 unit/ml) and 0.01 ml NADPH
(1 mM) for 30 min at 37(C. NO2
 levels were determined
spectrophotometrically at 540 nm by comparing the
absorbance of 0.1 ml sample after adding 0.1 ml Griess
reagent (sulfanilic acid (1% w/v) and N-(1-naphythyl)ethy-
lenediamine (0.1% w/v) in 5% phosphoric acid) to
a NaNO2 (1e100 mM) standard.
IMMUNOHISTOCHEMISTRY FOR iNOS DETECTION
The synovial samples were used to assess the expres-
sion of the iNOS enzyme, using a commercially available
rabbit anti-human iNOS antibody (Santa Cruz Biotechnol-
ogy, CA, USA). Brieﬂy, after deparafﬁnization, the tissues
were incubated with hydrogen peroxide and washed. After
incubation in citrate buffer, the tissues were subjected to
slight heating in a microwave oven. After overnight unspe-
ciﬁc blocking with rabbit serum, the samples were incubated
with the rabbit anti-iNOS antibody (diluted 1:100 in PBS
plus 1% of bovine serum albumin, 2 h). After rinsing, the
sections were incubated with a secondary biotinylated
anti-rabbit immunoglobulin G antibody. The reaction prod-
uct was detected with avidinebiotineperoxidase complex
(Vector Laboratories, Burlingame, CA), and the color of
the reaction was developed with diamino-benzidine tetrahy-
drochloride (DAB, Sigma, USA). The slides were counter-
stained with Mayer Hematoxylin.
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As a means of validating the hyperalgesic test in an OA
model, we administered either the non-selective cyclooxy-
genase (COX) inhibitor indomethacin (2 mg/kg/day s.c.
(subcutaneous)) dissolved in a 5% w/v NaHCO3 solution
or the selective COX-2 inhibitor meloxicam (Movatec e
BoehringereIngelheim Brasil Ltda.) (6 mg/kg/day i.p.), start-
ing 4 days after ACLT, until sacriﬁce, at 7 days. Another
group received morphine (200 mg) intra-articularly (i.art.),
at day 4, diluted in 50 ml of saline, and was compared to
a group that received a combined i.art. administration of
the m-opioid-receptor antagonist naloxone (500 mg) and
morphine (200 mg). Other groups received either the non-
selective NOS inhibitor L-NG-nitroarginine methyl ester
(L-NAME: 30 mg/kg/bid) or the selective iNOS inhibitor
N-(3-(aminomethyl)benzyl)acetamide (1400W: 0.5 mg/kg/
day), either 30 min before (prophylactic strategy) or starting
4 days after (therapeutic strategy) the ACLT until sacriﬁce,
at 7 days. Reversion of L-NAME inhibition was evaluated
by prior administration of L-arginine (500 mg/kg/bid), fol-
lowed by L-NAME. These groups were compared to groups
of animals subjected to the ACLT transection that received
the respective vehicles (non-terated (NT) groups). Indo-
methacin, L-NAME and L-arginine were purchased from
Sigma, St. Louis, MO, and 1400W was purchased from
Cayman Chem. Co., USA. Morphine and naloxone were
purchased from Laborato´rios Crista´lia Brasil Ltda.
STATISTICS
Results are presented as the meansSD (standard
deviation) of measurements made on six animals in eachgroup. Differences between means were compared using
one-way analysis of variance (ANOVA) followed by Tukey’s
test; P< 0.05 was considered as signiﬁcant.
Results
DEVELOPMENT OF THE JOINT HYPERALGESIA
IN THE ACLT MODEL
The Fig. 1(AeD) illustrates the kinetics of the develop-
ment of hyperalgesia in the ACLT (OA), sham, and control
groups. Animals of the OA group developed a signiﬁcant
increase in the PET, as compared to both the sham
and control groups (P< 0.05). The increase in the PET
started in the ﬁrst day after the surgical procedure and
reached its peak during the ﬁrst week in the OA group re-
maining elevated until the end of the second week post-
surgery.
ANALYSIS OF THE CELL INFLUX INTO THE JOINTS
The cell counts in the articular exudates did not differ be-
tween the three groups in any of the time points evaluated
(Table I). In all groups, there was predominance (80%) of
mononuclear cells in joint exudates.
KINETICS OF NO RELEASE INTO THE JOINT EXUDATES
Figure 2 illustrates the total amounts of nitrite in the differ-
ent groups, including baseline levels and at 7, 14, or 28
days after ACLT. The concentrations in the OA group
were signiﬁcantly increased (236%) compared to thoseFig. 1. Kinetics of the articular hyperalgesia in rats subjected to ACLT. A group of rats was subjected to ACLT (OA) (-), a sham group (;)
was subjected to the surgical procedure without ACLT and the control (naive) (,) group was not manipulated. The hyperalgesia was eval-
uated daily until 7 (A), 14 (B), 21 (C) or 28 days (D) after the procedure. Results are expressed as the meansSD of groups of six animals.
*P< 0.05 compared to the sham group. (One-way ANOVA followed by Tukey’s test.)
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(P< 0.05). As compared to the control (naive) group, the ni-
trite levels in the OA group were signiﬁcantly increased at
all time points evaluated (P< 0.05). Nitrite levels in the
sham and control groups did not differ signiﬁcantly.
EXPRESSION OF THE iNOS ACTIVITY IN THE SYNOVIA
The Fig. 3(AeF) illustrates the photomicrographs of
the immunostaining for iNOS activity in the synovia
obtained from control (B), sham (D), and OA (F) groups.
The Fig. 3(AeC) represents the synovia incubated with-
out the primary iNOS antibody. The immunostaining
was more intense in the synovia obtained from the
OA groups and it was more evident in the superﬁcial
(synovial) cells.
EFFECT OF THE ADMINISTRATION OF COX INHIBITORS,
MORPHINE AND OF NOS INHIBITORS IN THE JOINT PAIN
The prophylactic administration of either indomethacin or
meloxicam signiﬁcantly reduced the joint pain, as compared
to the NT group (P< 0.01) (Fig. 4). In addition, the local
(i.art.) administration of morphine did also signiﬁcantly re-
verse joint pain (Fig. 5). This effect was totally inhibited by
the combined administration of naloxone and morphine.
The effect of the prophylactic administration of the NOS
inhibitors in joint pain is illustrated in Fig. 6. Both L-NAME
and 1400W signiﬁcantly inhibited the pain, as compared
to the NT group (P< 0.001). The combined administration
Table I
CI into the articular exudates of rats subjected to ACLT. A group of
rats was subjected to ACLT (OA), a sham group was subjected to
the surgical procedure without ACLT and the control (naive) group
was not manipulated. The CI was assessed in the joint lavage
collected at 7, 14 or 28 days after the procedure. Results are
expressed as the meansSD of groups of six animals (one-way
ANOVA followed by Tukey’s test)
Group Cells/mm3
7 days 14 days 28 days
Naive 49 29 49 12 52 32
Sham 70 59 74 61 45 29
OA 45 39 42 19 69 39
Fig. 2. Nitrite levels in the articular exudates of rats subjected to
ACLT. A group of rats was subjected to ACLT (OA), a sham group
was subjected to the surgical procedure without ACLT and the con-
trol (naive) group was not manipulated. Results are expressed as
the meansSD of groups of six animals. *P< 0.05 compared to
the sham group; #P< 0.05 compared to the naive group. (One-
way ANOVA followed by Tukey’s test.)of L-arginine and L-NAME reversed the effect of the later
compound, while L-arginine isolated had no effect. How-
ever, the therapeutic administration of L-NAME or 1400W
did not alter joint pain, as compared to the respective NT
group (P> 0.05).
Discussion
The integrity of the anterior cruciate ligament is essential
to knee joint stability, through reducing the intensity of
the anterior translocation and rotation of the tibia22. The de-
stabilizing effect secondary to the ACLT has been used as
a model for the study of joint alterations that closely
resemble those of human OA23. These include superﬁcial
ﬁbrillation, disorganization of the collagen and proteogly-
cans network, joint capsule thickening, and osteophyte
formation24.
We standardized a method for an objective and reproduc-
ible study of joint pain in the ACLT model in rats. In previous
studies, our group has utilized the test for articular incapac-
itation for the study of the hyperalgesia that occurs in the
zymosan-induced arthritis in rats. Using this approach, we
demonstrated that sensitization of the periarticular tissues
is involved in the hyperalgesia development21.
The test for articular incapacitation in rats was originally
described as a method that allows a quantitative, reproduc-
ible approach to study experimental joint pain. Measures
taken are independent of the observer, thus avoiding sub-
jective and non-parametric results. In this method, a com-
puter-assisted device measures the time that the animal
walks without touching the surface of a rotating cylinder.
This period, called the PET, is assumed to be directly pro-
portional to the articular incapacitation, and represents joint
pain. In their original report, the authors showed that the
commonly used analgesic and/or anti-inﬂammatory com-
pounds such as indomethacin, sodium diclofenac, dypirone,
as well as morphine, provided, as expected, inhibition of
joint pain that occurs as a consequence of the injection of
carrageenin into the knee20. In the present study, we
assumed that joint pain in an OA model would be less
prominent than that of the zymosan model21. Hence, we
adapted the prior method to the ACLT model by measuring
the PET for a more prolonged period, so that it would reﬂect
joint pain associated to weight bearing during movement.
After preliminary studies, we standardized a 10 min daily
recording period since it reproducibly reﬂected joint pain,
as observed visually.
In the present study, animals had increased PET as early
as 6 h (data not shown) after ACLT and PET remained ele-
vated until 14 days, as compared to the sham group. Indeed,
animals of the shamgroup did not display increase in PET, as
compared to naive animals. Though joint pain persisted until
14 days, it was maximal during the initial 7 days. In order to
avoid the possible bias linked to surgical trauma and also
due to ethical reasons to minimize animal suffering, we de-
cided to study the participation of inﬂammatory mediators in
the mechanisms of joint pain analyzing PET obtained from
4 to 7 days after ACLT.
Gait abnormalities following ACLT could be due to protec-
tive behavior to stabilize the joint. In a dog model, the reduc-
tion in the reaction force against the ﬂoor appeared to
depend on the integrity of the afferent nerves. Ipsilateral
ganglionectomy of the dorsal roots done prior to the ACLT
increased the vertical impulse force compared to controls,
although the increase was not statistically signiﬁcant in
that study25. Dogs with ACLT showed only temporary
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was subjected to the surgical procedure without ACLT and the control (naive) group was not manipulated. Figures represent the naive, sham
and OA groups, respectively, in the presence (B, D, F) or absence (A, C, E) of the primary anti-iNOS antibody (original 400).decrease in the duration of stance phase26, whereas in-
creased extension of the knee with decreased ‘‘yield’’ dur-
ing weight acceptance was seen during the entire
observation period25,26. Increased knee extension likely de-
creases demands on the quadriceps muscle when landing
on the affected extremity and therefore reduces anterior
tibial translation. Gait analysis has shown comparable
adaptations in ACL deﬁcient humans, i.e., quadriceps
avoidance gait27. Development of such adaptations in the
rat may explain the return to normal PET after 2 weeks,
as seen in this study.
There are some reports of methods aiming to evaluate
joint pain in experimental OA. Dogs presenting hip dyspla-
sia had locomotor alterations that were interpreted as signs
of pain18. In the iodoacetate OA model in rats, a reduction of
the force derived from the injected hind paw was assumed
as reﬂecting joint hyperalgesia28. More recently, a quantita-
tive approach was used to measure allodynia and reﬂected
paw-hyperalgesia in the iodoacetate model19. Our present
work adds to these previous reports since we measured
joint pain associated to joint instability and development of
OA. We believe that pain on weight bearing, as assessedin the present study, represents a major component of the
multifactorial mechanism of joint pain in OA.
Methods to evaluate joint pain include pharmacological
modulation by classical analgesic and/or anti-inﬂammatory
compounds. We found that both indomethacin and meloxi-
cam signiﬁcantly inhibited joint pain, as compared to
vehicle-treated animals. Besides useful to validate the
method, this result clearly suggests a prostanoid compo-
nent participating in joint pain of the ACLT model.
In another attempt to further characterize the joint pain,
we tested the efﬁcacy of the classical opioid-receptor ago-
nist morphine. The local administration of morphine signiﬁ-
cantly inhibited joint pain. This effect was inhibited by the
combined administration of the m-opioid-receptor antago-
nist, naloxone, and morphine. We found that intra-peritoneal
administration of morphine (6 mg/g) inhibited joint pain
(data not shown). However, in order to avoid a systemic
sedative effect, we chose to evaluate morphine i.art. In
addition to the indication of the participation of endogenous
m-opioid-receptor agonists in joint pain, this result
strengthens the similarity of the pain, as measured in the
present model, to that observed in OA in humans1.
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rather than a behavioral component for the alteration in
PET.
The cell inﬂux (CI) into the joints in human OA is mild and
it is usually composed of lymphocytes and mononuclear
cells29,30. There were no signiﬁcant differences in cell
counts of the various groups. It was reported that dogs sub-
jected to ACLT presented a mild mononuclear cell inﬁltrate
in the synovium31. To our knowledge, this is the ﬁrst report
to directly quantitate CI into the joints in an OA model. Our
data suggest that cell inﬁltration does not contribute to joint
Fig. 5. Effect of the administration of morphine in the articular hy-
peralgesia of rats subjected to ACLT. i.art. morphine (200 mg)
was given at day 4 after ACLT. An NT group was subjected to
ACLT and received the vehicle. Another group received a combined
i.art. administration of the m-opioid-receptor antagonist naloxone
(500 mg) and morphine (200 mg). The PET represents the percent
inhibition of the hyperalgesia obtained at day 4, 30 min after the
i.art. injections, expressed as the means SD of groups of six
animals. *P< 0.05 compared to NT group; #P< 0.001 compared
to morphine. (One-way ANOVA followed by Tukey’s test.)
Fig. 4. Effect of the administration of COX inhibitors in the articular
hyperalgesia of rats subjected to ACLT. Either indomethacin (2 mg/
kg/d s.c.) or meloxicam (6 mg/kg/d s.c.) was given starting at 4 days
after the ACLT and then daily until sacriﬁce at day 7. An NT group
was subjected to ACLT and received the vehicle. The PET repre-
sents the maximal hyperalgesia obtained between days 4 and 7
after ACLT, expressed as the meansSD of groups of six animals.
*P< 0.01; **P< 0.001 compared to NT group. (One-way ANOVA
followed by Tukey’s test.)pain in the ACLT model in rats. We speculate that the sen-
sitization of periarticular structures accounts for this mecha-
nism. Direct stimulation of non-adrenergic/non-cholinergic
receptors present in the synovium32 may also contribute
to joint pain.
Increased nitrite levels have been reported in the synovial
ﬂuid of OA patients8,33. We found increased NO levels in
the joint exudates, being maximal at 7 days. Apart from
local endothelial cells, synoviocytes as well as chondro-
cytes are potential sources of NO release in joints7. Indeed,
normal cultured human chondrocytes express iNOS after
in vitro stimulation34. Chondrocytes obtained from dogs
subjected to ACLT produce NO spontaneously in vitro35,36
and chondrocytes from patients presenting OA express
the neuronal isoform of the NOS and spontaneously pro-
duce NO in vitro37. Compressive mechanical stress was
shown to induce the release of nitrite from bovine cartilage
slices in vitro38. It is known that ligamentous and meniscal
tears disturb the normal distribution of forces acting upon
the joint cartilage in vivo24. In the present study, since we
detected increased iNOS activity in the superﬁcial synovial
cells of the animals subjected to ACLT, we propose that
these cells and, possibly, chondrocytes are responsible
for the increased NO levels. Indeed, in synovia obtained
from OA patients, increased iNOS expression was present
in CD68þ macrophages39.
We found a close association between the increased NO
levels and development of joint pain. Prophylactic adminis-
tration of either L-NAME or 1400W signiﬁcantly inhibited
pain. Since L-NAME effect was abrogated by the combined
administration of L-arginine and considering the high selec-
tivity of 1400W for the iNOS isoform, it is our belief that the
antinociceptive effect of these compounds was mostly due
to a speciﬁc inhibitory effect of iNOS. On the other hand,
Fig. 6. Effect of the administration of NOS inhibitors in the articular
hyperalgesia of rats subjected to ACLT. Either the non-selective
NOS inhibitor L-NAME (30 mg/kg/bid i.p.) or the selective iNOS in-
hibitor 1400W (0.5 mg/kg/day s.c.) was given 30 min prior (prophy-
lactic) to ACLT or starting at day 4 (therapeutic) after ACLT and
then daily until sacriﬁce at day 7. An NT group was subjected to
ACLT and received the vehicle. L-arginine (L-ARG: 500 mg/kg/bid
s.c.), in combination with L-NAME or isolated, was given prior to
ACLT and then daily, until sacriﬁce. The PET represents the max-
imal hyperalgesia obtained between days 4 and 7 after ACLT,
expressed as the meansSD of groups of six animals. Results
are expressed as the means SD of groups of six animals.
*P< 0.001 compared to NT. (One-way ANOVA followed by Tukey’s
test.)
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egy), neither L-NAME nor 1400W showed an effect. These
data suggest, for the ﬁrst time, that iNOS activation is linked
to joint pain in the ACLT model. Hence, the prophylactic ad-
ministration of NOS inhibitors might block synoviocytes and/
or chondrocytes activation, thus inhibiting joint pain. How-
ever, in an ongoing process, NOS inhibitors do not display
intrinsic antinociceptive activity.
L-NAME was antinociceptive in the formalin test in the rat
paw as well as in the abdominal writhings test provoked by
acetic acid injection40. Intra-techal injection of the selective
iNOS inhibitors aminoguanidine or 2-amine-5,6-hydroxi-
methylthyazine inhibited carrageenin-induced thermal
hyperalgesia in rats41. The NO donor 3-morpholinosydnoni-
mine (SIN-1) promoted hyperalgesia in the paw-pressure
test in rats42, while intradermal injection of an NO donor pro-
duced pain in humans15,43. Paradoxical as it may seem,
there are also data reporting antinociceptive effects for
NO. In the paw-pressure test in rats, after injecting either
carrageenin or prostaglandin E2, the acetylcholine induced
analgesia was linked to the L-arginine:NO:cGMP (cyclic
guanosine monophosphate) system44. In humans, trans-
dermal nitrate patches, used as NO donors, provided relief
in post-surgical pain45 as well as in shoulder periarthritis
patients14. We have reported that NOS inhibitors display
anti-hypernociceptive activity in zymosan arthritis only
when used prophylactically, while sodium nitroprusside
and SIN-1 signiﬁcantly inhibited joint hyperalgesia16. There-
fore, a dual role for NO in the ACLT model seems probable.
Additionally, the indirect participation of NO in joint pain
through the release of reactive nitrogen species cannot be
ruled out. Though the present data argue against NOS in-
hibitors as pain killers in OA, the use of NO donors with
this purpose warrants further studies.
In conclusion, the present study presents a low-cost,
practical, easy-to-handle, reproducible, objective method
to directly assess joint pain in experimental OA in rats.
Using this method we found evidence that prostanoids
and NOS products play a role in joint pain.
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